ArticleResearch (Washington, D.C.)2026
Cell Segmentation as Strategic Decision Making.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell segmentation in imaging-based spatial transcriptomics (ST) relies on stained image segmentation or transcript clustering, but current methods are limited by dependence on manual annotations, sensitivity to staining quality and cell density, and lack of alignment with true transcriptomic profiles. We introduce RedeFISH, a reinforcement learning-based framework that formulates cell segmentation as a sequential strategic decision-making process. Through iterative optimization of the transcript assignment policy, RedeFISH aligns segmented cell expression profiles with single-cell expressions to achieve optimal segmentation. This approach enables staining-free, transcriptome-informed delineation of individual cells, thereby overcoming key limitations of existing methods. Benchmarking across multiple ST platforms shows that RedeFISH improves cosine similarity of segmented cell expression profiles by 9.7% on average and reduces root mean squared error (RMSE) by 13.9% compared with state-of-the-art methods. It also increases agreement between segmented and ground-truth cell regions by 19%, demonstrating improved accuracy and robustness. RedeFISH further imputes whole-transcriptome profiles from sparse ST measurements via spatially guided transfer from scRNA-seq data. The whole-transcriptome coverage enables unbiased and in situ prioritization of the critical regulators of spatial niches, e.g., mouse intestinal stem cell niches, and unlocks the possibility to delineate, with only one sample, the panoramic molecular and cellular changes along the whole developmental process from initiation to invasion for human cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.